Merck stock steadies as Keytruda drives Q1 2026 revenue growth
Published on 07/24/2026 at 13:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co., Inc. (ISIN US58933Y1055) remains heavily shaped by its oncology franchise, with Merck stock reflecting a business in which Keytruda now generates a substantial share of group sales and underpins recent revenue growth in 2026.
Keytruda lifts revenue growth
In the latest reported period for Merck & Co., Inc., Keytruda continued to be the main growth engine, with company disclosures and recent financial data indicating that the immuno-oncology therapy has reached multi-billion-dollar quarterly sales and is driving overall revenue higher compared with the prior year.
According to Merck & Co., Inc. investor materials for its most recent quarters, total company revenue was in the tens of billions of dollars on an annualized basis, with oncology now accounting for a growing proportion compared with legacy primary care and vaccine products.
Pipeline and R&D investment
Merck & Co., Inc. highlights in its research updates that it is investing several billions of dollars per year in research and development across oncology, vaccines, and other therapeutic areas, and that late-stage programs span a broad range of indications beyond the current Keytruda label.
Company communications emphasize that this pipeline spending has risen compared with earlier years as Merck aims to sustain revenue growth beyond the eventual loss of exclusivity for some of its current blockbusters.
More Merck & Co. background and filings
Further details on Merck & Co., Inc. financials, filings, and product updates can be found in regulatory disclosures and company investor relations material.
Keytruda anchors oncology portfolio
Beyond headline revenue, Merck & Co., Inc. regularly underscores that Keytruda has become one of the best-selling cancer medicines globally, with sales that have climbed steadily over recent years and that now account for a large share of the company’s oncology revenue.
Merck stock and market role
Merck stock trades in the United States and is widely followed as a major global pharmaceutical name, with its valuation and daily liquidity influenced by expectations for Keytruda, the broader late-stage pipeline, and the company’s capital allocation between dividends, buybacks, and business development.
Merck & Co. at a glance
- Company: Merck & Co., Inc.
- ISIN: US58933Y1055
- Ticker: NYSE: MRK
- Trading venue: NYSE
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
